Tracking down the molecular substrates of stress: New roles for p38α mapk and kappa-opioid receptors

Neuron

Volumn 71, Issue 3, 2011, Pages 383-385

  Muschamp, John W ^a   Van't Veer, Ashlee ^a   Carlezon, William A ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; CORTICOTROPIN RELEASING FACTOR; DOPAMINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE 14; MU OPIATE RECEPTOR; NEUROTROPHIN; NORADRENALIN; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ANALGESIA; ANXIETY; CELL FUNCTION; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DORSAL RAPHE NUCLEUS; DRUG MECHANISM; DRUG SEEKING BEHAVIOR; DRUG TARGETING; DYSPHORIA; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; GENETIC ENGINEERING; HUMAN; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; MONOAMINE RELEASE; MOOD; MOTIVATION; NOCICEPTION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; RECEPTOR BLOCKING; SEROTONINERGIC NERVE CELL; SHORT SURVEY; STRESS; VIRAL GENE DELIVERY SYSTEM;

EID: 79961202746     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2011.07.018     Document Type: Short Survey

References (15)

1. Bruchas M.R., Chavkin C. Psychopharmacol. 2010, 210:137-147.
2. Bruchas M.R., Schindler A.G., Shankar H., Messinger D.I., Miyatake M., Land B.B., Lemos J.C., Hagan C., Neumaier J.F., Quintana A., et al. Neuron 2011, 71:498-511. this issue.
3. Carlezon W.A., Thomas M. Neuropharmacol. 2009, 56(Suppl 1):122-132.
4. Carlezon W.A., Béguin C., Knoll A.T., Cohen B.M. Pharmacol. Ther. 2009, 123:334-343.
5. Duman R.S., Monteggia L.M. Biol. Psychiatry 2006, 59:1116-1127.
6. Hauger R.L., Risbrough V., Oakley R.H., Olivares-Reyes J.A., Dautzenberg F.M. Ann. N Y Acad. Sci. 2009, 1179:120-143.
7. Heninger G.R., Delgado P.L., Charney D.S. Pharmacopsychiatry 1996, 29:2-11.
8. Knoll A.T., Muschamp J.W., Sillivan S.E., Ferguson D., Dietz D.M., Meloni E.G., Carroll F.I., Nestler E.J., Konradi C., Carlezon W.A. Biol. Psychiatry 2011, Published online April 29, 2011.
9. Koob G.F. Biol. Psychiatry 1999, 46:1167-1180.
10. Krishnan V., Han M.H., Graham D.L., Berton O., Renthal W., Russo S.J., Laplant Q., Graham A., Lutter M., Lagace D.C., et al. Cell 2007, 131:391-404.
11. Land B.B., Bruchas M.R., Schattauer S., Giardino W.J., Aita M., Messinger D., Hnasko T.S., Palmiter R.D., Chavkin C. Proc. Natl. Acad. Sci. USA 2009, 106:19168-19173.
12. Meloni E.G., Reedy C.L., Cohen B.M., Carlezon W.A. Biol. Psychiatry 2008, 63:832-839.
13. Pasternak G.W. Proc. Natl. Acad. Sci. USA 1980, 77:3691-3694.
14. Pfeiffer A., Brantl V., Herz A., Emrich H.M. Science 1986, 233:774-776.
15. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B., Weinstein H., Javitch J.A., Roth B.L., Christopoulos A., Sexton P.M., et al. J. Pharmacol. Exp. Ther. 2007, 320:1-13.